Setting up a peptide research lab — whether a dedicated animal facility suite or a shared bench space — requires careful planning across four dimensions: equipment, sterile technique, regulatory compliance, and documentation. This guide covers each dimension with actionable specifics, from minimum viable equipment lists to IACUC documentation requirements. Whether you are running your first GLP-1 agonist study in DIO mice or scaling up to a multi-compound longevity protocol, these standards apply.
Minimum Equipment List
Not every lab needs a full GMP suite, but certain equipment is non-negotiable for reproducible peptide research. The following table covers what is essential versus strongly recommended:
| Equipment | Category | Why Essential |
|---|---|---|
| Analytical balance (0.1 mg precision) | Essential | Accurate vial mass verification; catch underfilled vials before reconstitution |
| Calibrated micropipettes (0.5–10 µL, 10–100 µL, 100–1000 µL) | Essential | Accurate peptide dilution and dosing; use positive-displacement pipettes for viscous solutions |
| Vortex mixer | Do NOT use | Vortexing denatures peptides — use gentle swirling only (see Reconstitution section) |
| Low-speed rocking/orbital shaker | Recommended | Gentle agitation for reconstitution of stubborn lyophilized cakes at 4°C |
| Refrigerator (2–8°C, dedicated) | Essential | Reconstituted peptide storage; do not store with food or chemicals |
| −20°C freezer | Essential | Lyophilized peptide long-term storage; must cycle to <−15°C |
| −80°C freezer | Strongly recommended | Long-term reconstituted aliquot storage; NAD+ and oxidation-sensitive compounds require −80°C |
| Laminar flow hood (Class II BSC) | Essential for in vivo work | Sterile reconstitution environment; required by most IACUC protocols |
| Cold centrifuge (4°C capable) | Recommended | Clarification of reconstituted solutions; spin at 500 × g to check for particulates |
| UV-Vis spectrophotometer or NanoDrop | Recommended | Concentration verification; 259 nm for NAD+; 280 nm for Trp/Tyr-containing peptides |
| Amber glass vials (1–2 mL) | Essential | Light-sensitive peptide storage; GHK-Cu, NAD+, PT-141 require amber only |
| Low-bind microcentrifuge tubes (1.5 mL) | Essential for dilute solutions | Peptides adsorb to standard polypropylene at ≤10 µg/mL; low-bind tubes prevent surface loss |
| Insulin syringes (28–31G, 0.5 mL) | Essential | Subcutaneous injections; 29G preferred for minimal tissue trauma |
| Sharps disposal container (UN-approved) | Essential / Regulatory | Required for all needle and syringe disposal; must be puncture-resistant |
| pH meter and calibration buffers | Recommended | Verify reconstitution buffer pH; particularly important for oxytocin, LL-37, and acid-labile peptides |
| Timer / stopwatch | Essential | Standardize endpoint timing post-injection; behavioral endpoints are highly time-sensitive |
Sterile Technique for Peptide Reconstitution
Contamination during reconstitution is the single most common source of adverse events in in vivo peptide studies. A rigorous sterile technique protocol prevents bacterial introduction, endotoxin contamination, and cross-contamination between compounds. Follow this sequence for every reconstitution:
- Work inside a Class II Biosafety Cabinet (BSC) — wipe interior with 70% ethanol and allow 5 minutes of airflow before starting
- Wear nitrile gloves; change gloves between compounds to prevent cross-contamination
- Swab the rubber septum of each vial (peptide vial, BAC water vial) with a 70% isopropyl alcohol swab; allow 30 seconds to dry before piercing
- Use a fresh sterile syringe and needle for each compound — never reuse needles between vials
- For BAC water addition: inject the BAC water slowly along the inner wall of the vial, not directly onto the lyophilized cake (prevents denaturation from direct jet impact)
- Swirl gently for 60 seconds; do not vortex; if cake does not dissolve, place on orbital shaker at 4°C for 15–30 minutes
- Visually inspect for clarity: solution should be clear and colorless (or faint blue-violet for GHK-Cu); discard any cloudy, particulate, or discolored solutions
- If clarity is uncertain, centrifuge at 500 × g for 2 minutes at 4°C and inspect supernatant
- Label reconstituted vials immediately with: compound name, lot number, concentration, reconstitution date, expiration date, researcher initials
Needle and Sharps Disposal Protocol
Improper sharps disposal is a regulatory violation in every US jurisdiction and creates biohazard risk for staff. Follow these standards:
- Never recap needles with two hands — use single-hand scoop technique or a needle-cap holder if recapping is necessary
- Dispose of needles and syringes immediately after use — never leave exposed sharps on the bench
- Use only UN-approved, puncture-resistant sharps containers; fill to no more than the marked fill line (typically ¾ full)
- Seal filled containers and store in a designated area until pick-up by a licensed medical waste contractor
- Document sharps disposal in your institutional waste log if required by your facility
- For animal studies: animal carcasses, soiled bedding, and biological waste may require separate biohazard disposal streams — check with your institutional biosafety officer
IACUC Compliance and Animal Handling Certifications
Any research involving vertebrate animals in the United States requires Institutional Animal Care and Use Committee (IACUC) approval. This is not optional — unapproved animal research is a federal violation under the Animal Welfare Act. Key requirements include:
| Requirement | Details | Typical Timeline |
|---|---|---|
| IACUC Protocol Submission | Describe species, procedures, compounds, doses, pain/distress level, humane endpoints | 4–8 weeks for review and approval |
| Species-Specific Training | Completion of institutional training modules for handling, dosing (SC/IP/IV), blood collection, and euthanasia methods | 1–2 weeks; must be completed before animal work begins |
| Animal Facility Access | IACUC approval required before facility badge/key access is granted | After protocol approval |
| Occupational Health Clearance | Allergy screening and health questionnaire for personnel working with rodents | 1–2 weeks; required by most institutions |
| 3Rs Justification | Replace (non-animal alternatives), Reduce (minimum effective group sizes), Refine (minimize pain/distress) — must be addressed in every IACUC protocol | Part of protocol submission |
| Annual Protocol Review | IACUC protocols are typically approved for 1–3 years with annual review renewals | Ongoing |
Practical tip: If you are new to IACUC submission, request a pre-submission consultation with your IACUC coordinator. They can flag issues before you submit, reducing back-and-forth cycles that add weeks to your start timeline.
Record Keeping Requirements
Reproducibility in peptide research depends on documentation quality. Underdocumented studies cannot be replicated, and in institutional settings, inadequate records are a common cause of audit findings. Minimum record keeping fields for each study:
- Study ID and title, IACUC protocol number, start and end dates
- Compound(s): supplier, lot number, purity (% from COA), molecular weight, CAS number, storage conditions
- Reconstitution details: solvent used, concentration (mg/mL or µg/mL), date reconstituted, expiration date, vial ID
- Animal details: species, strain, vendor, age at study start, sex, body weight at randomization
- Randomization method: how animals were assigned to groups (see Blinding section below)
- Dosing log: for each animal on each dosing day — date, time, body weight, calculated dose (mg/kg), actual volume injected, injection site, administrator initials
- Adverse events: any death, unexpected weight loss (>20% in 48h), visible injection site reaction, or behavioral abnormality
- Endpoint data: raw measurements with date/time collected, instrument calibration dates, analyst initials
- COA file: retain a copy of the COA for every compound lot used; attach to study file
COA Documentation Protocol
The Certificate of Analysis is your primary quality assurance document. A complete COA verification workflow for each incoming compound:
- Verify lot number on COA matches the vial label — mismatch is a disqualifying event
- Check testing laboratory accreditation: ISO/IEC 17025 accreditation for the HPLC and MS methods is the standard; Janoshik Analytical and Freedom Diagnostics both meet this standard
- Confirm HPLC purity ≥99% (≥98% acceptable for exploratory studies); check that the chromatogram shows a single dominant peak with documented retention time and column specification
- Verify MS identity: [M+H]⁺ or [M+2H]²⁺ mass should match the theoretical monoisotopic mass within ±0.5 Da; check isotope envelope where provided
- Check endotoxin result if in vivo use is planned: LAL result should be <1 EU/mg for SC/IP rodent dosing (USP threshold for rodents is approximately 5 EU/kg/hr — calculate your actual dose-based threshold)
- File the verified COA in your study records before the first use of that lot; do not begin dosing with an unverified lot
Blinding and Randomization SOPs
Bias in peptide research is primarily introduced through two mechanisms: non-random group assignment and unblinded outcome assessment. Both are preventable with standardized SOPs.
Randomization
Animals should be randomized to groups after baseline measurements are complete (body weight, blood glucose, etc.) using one of these methods:
- Simple randomization: assign each animal a random number (from a random number table or software) and allocate to groups in order — adequate for n ≥ 10 per group
- Block randomization: create blocks matched on key baseline variables (sex, body weight quartile, litter) and randomize within blocks — preferred for n < 10 per group to ensure balance
- Stratified randomization: pre-stratify by baseline body weight or blood glucose, then randomize within strata — minimizes baseline covariate imbalance in small studies
- Record the randomization method and seed in your study records so the assignment can be reconstructed or audited
Blinding
Single-blinding (the dosing technician knows treatment assignment but the outcome assessor does not) is the minimum standard for behavioral and histological endpoints. Double-blinding (neither doser nor assessor knows treatment) is preferred for primary efficacy endpoints:
- Use cage card codes (A, B, C...) rather than treatment names; maintain the treatment key separately under the study PI
- Prepare coded syringes in a separate room from the dosing area; the dosing technician sees only the code
- For behavioral tests (open field, elevated plus maze, Morris water maze): the observer should not know which group the animal is from; use video recording and have a blinded observer score the footage
- For histological scoring (wound healing, tumor burden): use random image labeling; the pathologist should score from randomized labeled images, not from treatment-labeled slides
- Break the blind only after all data collection is complete and locked; document the unblinding event with date and reason
A common oversight: changing the dose of a compound mid-study without a formal protocol amendment breaks the integrity of the study design. Any dosing change requires IACUC approval and a study record amendment before implementation.
Practical First-Protocol Checklist
- IACUC protocol approved and personnel training complete ✓
- Compounds ordered with lot-specific COAs; COAs verified and filed ✓
- Equipment calibration current (balance, pipettes, pH meter) ✓
- Laminar flow hood certified and UV lamp serviced ✓
- Reconstitution supplies in stock: BAC water, low-bind vials, amber vials, insulin syringes, alcohol swabs ✓
- Sharps container in place; biosafety waste bags available ✓
- Study record binder or electronic CRF set up with all required fields ✓
- Randomization complete; group codes assigned; treatment key sealed ✓
- Endpoint timing and blinding SOPs confirmed with all personnel before Day 1 ✓
- Adverse event reporting procedure confirmed with IACUC coordinator ✓